IL175965A0 - Montelukast free acid polymorphs - Google Patents
Montelukast free acid polymorphsInfo
- Publication number
- IL175965A0 IL175965A0 IL175965A IL17596506A IL175965A0 IL 175965 A0 IL175965 A0 IL 175965A0 IL 175965 A IL175965 A IL 175965A IL 17596506 A IL17596506 A IL 17596506A IL 175965 A0 IL175965 A0 IL 175965A0
- Authority
- IL
- Israel
- Prior art keywords
- free acid
- montelukast free
- acid polymorphs
- polymorphs
- montelukast
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54084004P | 2004-01-30 | 2004-01-30 | |
US58223704P | 2004-06-22 | 2004-06-22 | |
PCT/US2005/002898 WO2005074935A1 (fr) | 2004-01-30 | 2005-01-31 | Polymorphes d'acide sans montelukast |
Publications (1)
Publication Number | Publication Date |
---|---|
IL175965A0 true IL175965A0 (en) | 2006-10-05 |
Family
ID=34841113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL175965A IL175965A0 (en) | 2004-01-30 | 2006-05-28 | Montelukast free acid polymorphs |
Country Status (8)
Country | Link |
---|---|
US (1) | US20050187243A1 (fr) |
EP (1) | EP1708708A1 (fr) |
JP (1) | JP2007518826A (fr) |
KR (1) | KR20060117356A (fr) |
CA (1) | CA2554572A1 (fr) |
IL (1) | IL175965A0 (fr) |
MX (1) | MXPA06008584A (fr) |
WO (1) | WO2005074935A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE522507T1 (de) * | 2003-10-10 | 2011-09-15 | Synhton B V | Montelukast in fester phase |
CA2554789A1 (fr) * | 2004-01-30 | 2005-08-18 | Teva Pharmaceutical Industries, Ltd. | Montelukast de sodium polymorphe |
JP2007532686A (ja) * | 2004-04-21 | 2007-11-15 | テバ ファーマシューティカル インダストリーズ リミティド | モンテルカストナトリウムを調製する方法 |
WO2006064269A2 (fr) * | 2004-12-17 | 2006-06-22 | Cipla Limited | Sels d'antagoniste de leukotriene |
JP2008510840A (ja) * | 2005-07-05 | 2008-04-10 | テバ ファーマシューティカル インダストリーズ リミティド | モンテルカストの精製 |
AR057909A1 (es) * | 2005-11-18 | 2007-12-26 | Synthon Bv | Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico. |
EA021960B1 (ru) * | 2005-12-30 | 2015-10-30 | Крка, Товарна Здравил, Д.Д., Ново Место | Таблетка, содержащая фармацевтически приемлемую соль монтелукаста в аморфной форме, и способ ее получения |
EP1803457A1 (fr) * | 2005-12-30 | 2007-07-04 | Krka Tovarna Zdravil, D.D., Novo Mesto | Composition pharmaceutique contenant du montelukast |
PT1818057E (pt) * | 2006-02-09 | 2010-06-18 | Teva Pharma | Formulações farmacêuticas estáveis de montelucaste de sódio |
WO2007107297A1 (fr) * | 2006-03-17 | 2007-09-27 | Synthon B.V. | Sel d'amantadine de montélukast |
EP1886997A1 (fr) * | 2006-08-09 | 2008-02-13 | Esteve Quimica, S.A. | Procédé de purification de montelukast |
EP1886998A1 (fr) * | 2006-08-09 | 2008-02-13 | Esteve Quimica, S.A. | Procédés de purification du montelukast et ses sels d'amine |
US7700776B2 (en) * | 2006-10-24 | 2010-04-20 | Formosa Laboratories, Inc. | Compounds and preparation for montelukast sodium |
PL205444B1 (pl) | 2007-05-02 | 2010-04-30 | Zak & Lstrok Ady Farmaceutyczn | Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego |
CZ302518B6 (cs) * | 2007-07-09 | 2011-06-29 | Zentiva, A. S. | Zpusob izolace a cištení montelukastu |
KR101072896B1 (ko) * | 2007-10-09 | 2011-10-17 | 한미홀딩스 주식회사 | 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법 |
CN102046602A (zh) * | 2008-04-25 | 2011-05-04 | 斯索恩有限公司 | 制备孟鲁司特中间体的方法 |
KR101123292B1 (ko) * | 2008-09-26 | 2012-03-19 | 주식회사 엘지생명과학 | 몬테루카스트 나트륨염의 제조방법 |
WO2010112222A1 (fr) | 2009-03-31 | 2010-10-07 | Krka, D.D., Novo Mesto | Cristallisation progressive en émulsion |
EP2287154A1 (fr) | 2009-07-14 | 2011-02-23 | KRKA, D.D., Novo Mesto | Synthèse efficace pour la préparation de montelukast |
WO2011121091A1 (fr) | 2010-03-31 | 2011-10-06 | Krka, D.D., Novo Mesto | Synthèse efficace pour la préparation de montélukast et nouvelle forme cristalline d'intermédiaires dans celle-ci |
KR102495018B1 (ko) | 2013-11-15 | 2023-02-06 | 아케비아 테라퓨틱스 인코포레이티드 | {[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노}아세트산의 고체형, 이의 조성물 및 용도 |
IT201900008340A1 (it) | 2019-06-07 | 2020-12-07 | Genetic S P A | Sali di montelukast e loro composizioni farmaceutiche |
AU2021215849B2 (en) | 2020-02-03 | 2023-08-03 | Taro Pharmaceutical Industries Ltd. | Topical montelukast formulations |
CN116509810B (zh) * | 2023-05-18 | 2024-03-29 | 牡丹江恒远药业股份有限公司 | 一种孟鲁司特钠片剂及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0480717T3 (da) * | 1990-10-12 | 1999-02-08 | Merck Frosst Canada Inc | Umættede hydroxyalkylquinolinsyrer som leukotrienantagonister |
EP0480716A1 (fr) * | 1990-10-12 | 1992-04-15 | Merck Frosst Canada Inc. | Acides hydroxyalkylquinoliniques saturés comme antagonistes de leukotriène |
US5565473A (en) * | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
TW416948B (en) * | 1993-12-28 | 2001-01-01 | Merck & Co Inc | Process for the preparation of leukotriene antagonists |
US5523477A (en) * | 1995-01-23 | 1996-06-04 | Merck & Co., Inc. | Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid |
GB9812413D0 (en) * | 1998-06-10 | 1998-08-05 | Glaxo Group Ltd | Compound and its use |
WO2003066598A1 (fr) * | 2002-02-07 | 2003-08-14 | Dr. Reddy's Laboratories Ltd. | Nouvelles formes amorphes anhydres de sel de sodium de montelukast |
US20050107612A1 (en) * | 2002-12-30 | 2005-05-19 | Dr. Reddy's Laboratories Limited | Process for preparation of montelukast and its salts |
EP1633357A4 (fr) * | 2003-04-15 | 2010-02-10 | Merck & Co Inc | Forme polymorphe de sodium de montelukast |
CA2528228C (fr) * | 2003-06-06 | 2011-09-20 | Morepen Laboratories Limited | Une methode de preparation d'un sel sodique de montelukast sous forme amorphe |
ATE522507T1 (de) * | 2003-10-10 | 2011-09-15 | Synhton B V | Montelukast in fester phase |
US7189853B2 (en) * | 2004-04-15 | 2007-03-13 | Dr. Reddy's Laboratories Limited | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts |
JP2007532686A (ja) * | 2004-04-21 | 2007-11-15 | テバ ファーマシューティカル インダストリーズ リミティド | モンテルカストナトリウムを調製する方法 |
-
2005
- 2005-01-31 EP EP05712362A patent/EP1708708A1/fr not_active Withdrawn
- 2005-01-31 US US11/048,276 patent/US20050187243A1/en not_active Abandoned
- 2005-01-31 CA CA002554572A patent/CA2554572A1/fr not_active Abandoned
- 2005-01-31 KR KR1020067016358A patent/KR20060117356A/ko not_active Application Discontinuation
- 2005-01-31 MX MXPA06008584A patent/MXPA06008584A/es unknown
- 2005-01-31 JP JP2006551524A patent/JP2007518826A/ja active Pending
- 2005-01-31 WO PCT/US2005/002898 patent/WO2005074935A1/fr active Application Filing
-
2006
- 2006-05-28 IL IL175965A patent/IL175965A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20050187243A1 (en) | 2005-08-25 |
JP2007518826A (ja) | 2007-07-12 |
KR20060117356A (ko) | 2006-11-16 |
CA2554572A1 (fr) | 2005-08-18 |
WO2005074935A1 (fr) | 2005-08-18 |
EP1708708A1 (fr) | 2006-10-11 |
MXPA06008584A (es) | 2007-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL175965A0 (en) | Montelukast free acid polymorphs | |
HK1245264A1 (zh) | 多晶型 | |
IL208963A0 (en) | Substituted quinoline compounds | |
IL189895A0 (en) | Triarylcarboxylic acid derivative | |
IL185399A0 (en) | Pyridyl acetic acid compounds | |
EP1911738A4 (fr) | Composé de l acide phénoxyalkanoique | |
EP1735702A4 (fr) | Expressions regulieres polymorphes | |
IL175696A0 (en) | Montelukast sodium polymorphs | |
IL181857A0 (en) | Quinolone analogs | |
ZA200703436B (en) | Methods for increasing maize yields | |
HK1105199A1 (en) | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4- yl-benzothiazol-2-yl)-amide | |
EP2123752A4 (fr) | Nouvel acide nucléique | |
GB0603160D0 (en) | Nucleic acid | |
EP2077326A4 (fr) | Nouvel acide nucléique | |
IL179772A0 (en) | Leptomycin compounds | |
EP1912499A4 (fr) | Preparation de montelukast | |
GB0504314D0 (en) | Novel polymorph | |
IL181185A0 (en) | Novel polymorphs of azabicyclohexane | |
EP1788082A4 (fr) | Construction d'acides nucleiques | |
SG122904A1 (en) | Nucleic acid preparation | |
IL186301A0 (en) | Hydromorphone polymorphs | |
ZA200605575B (en) | Substituted quinoline compounds | |
EP1862464A4 (fr) | Nouveau derive acide aminophenylalcanoique cyclique | |
GB0519969D0 (en) | Quinoline compounds | |
IL185801A0 (en) | Hydrocodone polymorphs |